Drug Trial Radar · NCT05205330
Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Nov 23, 2021
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Rottapharm BiotechIndustry
- Sponsor type
- Industry
- Collaborators
- Agenus Inc.
- First posted
- Jan 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. The fixed-dose Expansion phase will be conducted at the recommended dose for expansion (RDE), with the purpose of generating additional and more robust safety and efficacy data. 27 patients are predicted in the Dose Escalation phase and 52 in the Expansion phase, respectively. The Study Extension explores in other metastatic GI cancers the Vorbipiprant (CR6086) RDE obtained in the Main Study. 27 patients are predicted. No control arm was included, as the target patient population of this study consists of patients in whom the overall survival is less than 6 months and treatment options are very limited and often poorly tolerated, making unlikely that the study results can be significantly biased.
Conditions
- Refractory Metastatic Colorectal Cancer
- Solid Tumor
- Metastatic Microsatellite-stable Colorectal Cancer
- Mismatch Repair Protein Proficient
- Metastatic GI Cancers
- Gastric Cancer
Interventions
CR6086Drug
oral CR6086, twice a day for 14 days
AGEN2034Biological
AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of CR6086 combined with AGEN2034Time frame: From the time of the first dose up to 24 weeks of treatment
- Disease Control rate (DCR)Time frame: up to 24 weeks of treatment
- Objective Response Rate (ORR)Time frame: up to 24 weeks of treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Istituto Nazionale dei Tumori
Milan, Milano, Italy
Istituto Oncologico Veneto IRCCS
Padova, Padova, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.